<DOC>
	<DOCNO>NCT02841995</DOCNO>
	<brief_summary>This study conduct evaluate safety , tolerability , activity KD025 adult subject chronic Graft versus Host Disease ( cGVHD ) .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Activity KD025 Subjects With Chronic Graft Versus Host Disease</brief_title>
	<detailed_description>A total 48 subject enrol receive orally administer KD025 200 mg QD ( daily ) , KD025 200 mg BID ( twice daily ) , KD025 400 mg QD . Study drug administer 28-day cycle 6 cycle ( 24 week ) . Subjects may receive study drug inpatient outpatient setting .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Adult male female subject least 18 year age allogenic bone marrow transplant ( BMT ) hematopoietic stem cell transplantation ( HSCT ) . Receiving glucocorticoid therapy calcineurin therapy glucocorticoid therapy alone cGVHD study entry . Subjects calcineurin therapy , without glucocorticoid therapy , eligible . Subjects also receive therapy think immunosuppressive ( extracorporeal photopheresis ; ECP ) , consider enrollment study casebycase basis . Have persistent active cGVHD manifestation , define 2014 NIH Consensus Development Project Criteria Clinical trial cGVHD , least 2 month steroid therapy . No 3 prior line treatment cGVHD . Karnofsky Performance Scale &gt; 40 . Adequate organ bone marrow function evaluate 14 day prior enrollment follow : Absolute neutrophil count ≥ 1.5 × 109/L ( without myeloid growth factor within 1 week study entry ) Platelet count ≥ 50 × 109/L ( without transfusion thrombopoietin thrombopoietin analogue within 2 week study entry ) Adequate safety laboratory value : Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) ALT AST ≤ 3 × ULN Glomerular filtration rate ( GFR ) ≥ 30 mL/min/1.73 m2 use MDRD4 variable formula Female subject childbearing potential negative pregnancy test screening . Females childbearing potential define sexually mature woman without prior hysterectomy evidence menses past 12 month . However , woman amenorrheic 12 month still consider childbearing potential amenorrhea possibly due prior chemotherapy , anti estrogen , ovarian suppression . Women childbearing potential ( i.e. , menstruate woman ) must negative urine pregnancy test ( positive urine test confirm serum test ) document within 24hour period prior first dose study drug . Sexually active woman childbearing potential enrol study must agree use two form accept method contraception course study 3 month last dose study drug . Effective birth control include : IUD plus one barrier method ; Stable dos hormonal contraception least 3 month ( e.g. , oral , injectable , implant , transdermal ) plus one barrier method ; 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) ; A vasectomized partner For male patient sexually active partner premenopausal woman : agreement use two form contraception criterion 10 treatment period least 3 month last dose study drug . Able provide write informed consent prior performance studyspecific procedure . Female subject pregnant breastfeeding . Receiving investigational GVHD treatment within 28 day study entry . Has acute GVHD . Taking medication know moderate strong inhibitor CYP3A4 isozyme drug moderate strong CYP3A4 inducer . History evidence severe illness condition would make subject , opinion investigator , unsuitable study ( poorly control psychiatric disease coronary artery disease ) . Regular excessive use alcohol within 6 month prior study entry define alcohol intake &gt; 14 drink per week man &gt; 7 drink per week woman . Approximately 10 g alcohol equal one `` drink '' unit . One unit equal 1 ounce distil spirit , one 12ounce beer , one 4ounce glass wine . Known history human immunodeficiency virus ( HIV ) active hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) . Diagnosed another malignancy ( malignancy transplant perform ) within 3 year enrollment , exception completely resect basal cell squamous cell carcinoma skin , resect situ cervical malignancy , resect breast ductal carcinoma situ , lowrisk prostate cancer curative resection . Relapse underlie cancer posttransplant lymphoproliferative disease time screen . Has previous exposure KD025 know allergy/sensitivity KD025 ROCK2 inhibitor . Taking immunosuppressant drug GVHD , include mTor inhibitor ( Note : Only steroid , calcineurin inhibitor , ECP acceptable ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cGVHD</keyword>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Steroid refractory chronic graft v host disease ( cGVHD )</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Corticosteroids</keyword>
</DOC>